Loading
institutionsInstitution
American Society of Hematology
The world's largest haematology society, whose December annual meeting is where the pivotal leukaemia, lymphoma and myeloma results are first presented.
Also called: ASH
Overview
Founded in 1958, ASH has more than 18,000 members and publishes Blood and Blood Advances. Its annual meeting, held each December, is the venue for the major blood cancer trials, from CAR-T and bispecific antibody results to venetoclax combinations and MRD-guided therapy, and its late-breaking abstract session regularly changes practice. ASH issues clinical practice guidelines, runs the ASH Research Collaborative with its data hub and the Sickle Cell Disease and Cancer Clinical Trials Networks, funds scholar awards and global capacity building, and advocates on drug access and research funding. ASH-EHA and ASH-ASCO joint guidelines link it to its European and oncology counterparts.
Location
Washington, DC, US
Type
consortium
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#196 · 28 points (0 Newsweek + 0 NCI + 28 from 14 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to American Society of Hematology, including child institutions. 4 works · 22 citations · 100% open access · 25% clinical trials · 0% reviews.
Oncology works per year
22022
02023
02024
12025
12026
Most works
- Ashok Kumbamu2 works
- Robby Reynolds2 works
- Urshila Durani2 works
- Alfred Ian Lee2 works
- Martina Murphy2 works
- Lachelle D. Weeks2 works
- Devika Das2 works
- Ariela L. Marshall2 works
- Ajay Major2 works
- Elizabeth Henry2 works
Most cited
| Work | Journal | Year | Citations |
|---|---|---|---|
| Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment 10.1200/op.21.00630 · open access | JCO Oncology Practice | 2022 | 14 |
| Impact of COVID-19 on Hematology-Oncology Fellowship Programs: A Quantitative and Qualitative Survey Assessment of Fellowship Program Directors 10.1200/op.21.00634 · open access | JCO Oncology Practice | 2022 | 7 |
| Reconstructing Dermatology Education: The Backward Design and Curricular Content Expansion 10.1111/tct.70200 · open access | The Clinical Teacher | 2025 | 1 |
| Does size matter? Impact Of Body Mass Index On Outcome Of Anti-CD19 CAR-T Cell Therapy For B-Cell Lymphoma 10.1016/j.bict.2026.100086 · open access | Blood Immunology & Cellular Therapy | 2026 | 0 |
- ASH Annual Meeting (December)
- Blood and Blood Advances
- Clinical practice guidelines
- ASH Research Collaborative data hub
- Scholar awards and global programmes
Robert Negrin
President of the American Society of Hematology (2026)
HaematologyBlood and marrow transplantationCellular therapy
Stanford transplant physician and cellular immunologist who is President of the American Society of Hematology for 2026.
Kenneth C. Anderson
Kraft Family Professor of Medicine; Director, Jerome Lipper Multiple Myeloma Center
Multiple myelomaProteasome inhibitorsImmunomodulatory drugs
Translated bortezomib and lenalidomide from bench to bedside, helping turn myeloma from a two-year to a decade-plus disease.
Ross L. Levine
Chair, Center for Hematologic Malignancies; Member, Human Oncology and Pathogenesis Program
Myeloid malignanciesClonal haematopoiesisJAK2 and epigenetic regulators
Discovered the JAK2 mutation behind most myeloproliferative neoplasms and defined the genetics of clonal haematopoiesis.
Benjamin L. Ebert
President and Chief Executive Officer
Myeloid malignanciesClonal haematopoiesisMolecular glue degraders
Discovered how lenalidomide works, launching the field of molecular-glue degraders, and defined clonal haematopoiesis before leading Dana-Farber.
Similar pages
- CompanyHOVON
Shares European Hematology Association, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Chronic lymphocytic leukaemia.
- CompanyGIMEMA
Shares European Hematology Association, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Chronic lymphocytic leukaemia.
- IdeaPlan the second CAR-T target before the first one is lost
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, CAR-T cell therapy, Acute lymphoblastic leukaemia.
- TermLeukaemia (tissue type)
Shares Robert Negrin, Minimal / molecular residual disease (MRD), Chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia.
- InstitutionIRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola
Shares Bispecific antibodies, Hodgkin lymphoma, CAR-T cell therapy, Acute myeloid leukaemia.
- PersonJeffrey Miller
Shares Blood Advances, Blood.
- InstitutionIUCT Oncopole (Institut Universitaire du Cancer de Toulouse)
Shares Minimal / molecular residual disease (MRD), Bispecific antibodies, MRD / molecular residual disease testing, CAR-T cell therapy.
- TreatmentclonoSEQ
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia.